Save time and jump to the most important pieces.
6-K - WARRANTEE INC. (0001900564) (Filer)
6-K - WARRANTEE INC. (0001900564) (Filer)
6-K - WARRANTEE INC. (0001900564) (Filer)
Tokyo, Japan, April 19, 2024 (GLOBE NEWSWIRE) -- Warrantee Inc. (NASDAQ:WRNT) (the "Company" or "Warrantee"), a Japanese marketing and market research technology company, today announced that the Company received a staff determination letter (the "Letter"), on April 15, 2024, from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, due to the Company's failure to regain compliance with a minimum bid price of $1.00 per share requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Requirement"), the Staff has determined (the "Determination") that Company's securiti
Tokyo, Japan, April 10, 2024 (GLOBE NEWSWIRE) -- Warrantee Inc. (NASDAQ:WRNT) (the "Company" or "Warrantee"), a Japanese marketing and market research technology company, today announced that it received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on April 4, 2024 stating that, as a result of not having timely filed its interim report on Form 6-K for the six months ended September 30, 2023, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(2), which requires each foreign private issuer to submit on a Form 6-K an interim balance sheet and income statement as of the end of its second quarter to the U.S. Securities and Exchange Commission. This notice ha
TOKYO, Japan, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Warrantee Inc. (NASDAQ:WRNT) (the "Company" or "Warrantee"), a Japanese marketing and market research technology company, today announced that it had received a letter from the Nasdaq Office of General Office dated February 1, 2024, confirming that the Company had regained compliance with Nasdaq's filing requirement set forth in Listing Rule 5250(c)(1), since the Company filed its Form 20-F for the period ended March 31, 2023 on January 31, 2024. As a result, the scheduled hearing before the Hearings Panel on February 8, 2024 relating to the delisting determination resulting from the failure to file such Form 20-F had been cancelled and the m
Shares of Doximity, Inc. (NYSE:DOCS) rose sharply in today's pre-market trading reported stronger-than-expected financial results for the fourth quarter on Thursday. Doximity's fourth-quarter revenue increased 6% year-over-year to $118.1 million, which beat the consensus estimate of $116.4 million, according to Benzinga Pro. The company reported adjusted earnings of 25 cents per share, beating analyst estimates of 20 cents per share. The company said it expects first-quarter revenue to be between $119.5 million and $120.5 million versus estimates of $119.23 million. Doximity shares jumped 13.7% to $27.00 in the pre-market trading session. Here are some other stocks moving in pre-
Shares of Alcon Inc. (NYSE:ALC) rose sharply in today's pre-market trading following better-than-expected first-quarter earnings. Alcon posted adjusted earnings of 78 cents per share, beating market expectations of 63 cents per share. The company's quarterly sales came in at $2.444 billion versus estimates of $2.462 billion, according to data from Benzinga Pro. Alcon shares jumped 10.8% to $89.40 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers GameStop Corp. (NYSE:GME) gained 40.2% to $42.70 in pre-market trading after jumping over 74% on Monday. Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) gained 39.2% to $0.08
Shares of GeneDx Holdings Corp. (NASDAQ:WGS) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results and raised its FY2024 sales guidance. GeneDx reported quarterly losses of 33 cents per share which beat the analyst consensus estimate of losses of 67 cents. The company reported quarterly sales of $62.422 million which beat the analyst consensus estimate of $49.463 million, according to data from Benzinga Pro. GeneDx raised its full-year 2024 revenue guidance to between $235 million and $245 million, up from $220 million to $230 million, and expanded its full-year 2024 adjusted gross margin profile to at least 60% from